13 completed, 3 terminated, 3 unknown, 3 withdrawn. 7 Phase 2, 3 Not applicable, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Unknown 3, Withdrawn 1 |
| Not applicable | 3 | Completed 2, Terminated 1 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow SARS Pneumonia: new trials by email Literature Review of SARS Pneumonia trials Research Report on SARS Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Characteristics of Patients With COVID-19 in Meta State, Colombia COVID, SARS-CoV 2 | Withdrawn | Hospital Departamental de Villavicencio | 2021-09-01 | 2023-07-05 | ||
| Follow-up of Covid-19 Long Term Sequelae Not applicable (observational study) - COVID-19 Pneumonia, COVID-19 Respiratory Infection | Completed | Azienda Ospedaliera Universitaria Integrata Verona | 7599 | 2021-04-16 | 2024-10-28 | |
| Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2 Covid19, SARS-CoV Infection | Completed | NMC Specialty Hospital | 35 | 2021-03-29 | 2021-05-11 | |
| Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects Fostamatinib, Placebo - Covid19, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Completed | Rigel Pharmaceuticals | 280 | 2021-03-25 | 2023-08-18 |
| Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand Normal Saline, NDV-HXP-S vaccine - Covid-19, SARS Pneumonia | Phase 1 / Phase 2 | Completed | Mahidol University | 455 | 2021-03-20 | 2022-11-15 |
| A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1) COVIVAC, Phosphate-buffered saline - COVID-19 Disease, SARS Pneumonia | Phase 1 | Completed | Institute of Vaccines and Medical Biologicals, Vietnam | 120 | 2021-03-10 | 2025-02-13 |
| Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management Niclosamide Oral Tablet - Covid-19, SARS Pneumonia | Phase 2 | Unknown | University of Baghdad | 150 | 2021-01-03 | 2021-06-22 |
| Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19. Vitamin D, PLACEBO - SAR, SARS Pneumonia | Phase 3 | Completed | Bioaraba Health Research Institute | 108 | 2020-11-09 | 2022-07-15 |
| Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study) Fibreoptic Endoscopic Evaluation of Swallowing (FEES), Videofluoroscopy, Dysphagia Handicap Index (DHI) - Dysphagia, Dysphonia | Completed | Cambridge University Hospitals NHS Foundation Trust | 50 | 2020-09-15 | 2025-06-29 | |
| Cardiovascular Implications of COVID-19 SARS-CoV 2, SARS Pneumonia | Terminated | University of Texas Southwestern Medical Center | 42 | 2020-09-01 | 2023-05-23 | |
| A Study of Combination Therapies to Treat COVID-19 Infection hydroxychloroquine, Azithromycin, Ritonavir - COVID, COVID-19 | Phase 2 | Withdrawn | ProgenaBiome | 2020-07-01 | 2021-04-08 | |
| Glycine Supplement for Severe COVID-19 Glycine - COVID-19, SARS-CoV Infection | Not applicable | Terminated | Instituto Nacional de Enfermedades Respiratorias | 59 | 2020-06-15 | 2022-08-04 |
| Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial Convalescent Plasma of patients with COVID-19, placebo (hartmann plus albumine) - SARS Pneumonia | Phase 2 | Completed | Grupo Mexicano para el Estudio de la Medicina Intensiva | 42 | 2020-05-20 | 2020-12-21 |
| Baricitinib Compared to Standard Therapy in Patients With COVID-19 Baricitinib Oral Tablet - Covid-19, SARS-CoV 2 | Phase 2 | Unknown | Azienda Ospedaliero, Universitaria Pisana | 126 | 2020-05-20 | 2020-05-20 |
| Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth Therapy Intervention - SARS-CoV 2, SARS Pneumonia | Not applicable | Completed | University of Missouri-Columbia | 26 | 2020-05-19 | 2021-02-08 |
| Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Tocilizumab - COVID, SARS Pneumonia | Phase 3 | Terminated | Beneficência Portuguesa de São Paulo | 129 | 2020-05-08 | 2020-08-26 |
| Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma - Corona Virus Infection, SARS-CoV 2 | Phase 2 | Completed | University of Virginia | 29 | 2020-05-05 | 2022-04-01 |
| Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure Respiratory mechanics measurement, Gas exchange measurement - SARS Pneumonia | Completed | I.M. Sechenov First Moscow State Medical University | 117 | 2020-05-01 | 2020-08-27 | |
| Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey Critical Illness, Sars-CoV2 | Completed | Centre Hospitalier Universitaire de Nīmes | 1784 | 2020-04-09 | 2020-12-19 | |
| The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19 Pulmonary Physiotherapy Techniques - Covid-19, Pneumonia | Not applicable | Completed | Tehran University of Medical Sciences | 40 | 2020-04-02 | 2020-06-02 |
Showing 20 of 22. Sign in to see all of them.
COVID-19 (14) · Coronavirus Infections (7) · Severe Acute Respiratory Syndrome (6) · Pneumonia, Viral (5) · Pneumonia (4) · Disease (2) · Critical Illness (1) · Cytokine Release Syndrome (1) · Deglutition Disorders (1) · Dysphonia (1) · Infections (1) · Patient Compliance (1) · Respiratory Distress Syndrome (1) · Stress Disorders, Post-Traumatic (1) · Voice Disorders (1)
Coronaviridae Infections (17) · Nidovirales Infections (17) · RNA Virus Infections (17) · Virus Diseases (17) · Infections (16) · Lung Diseases (16) · Respiratory Tract Diseases (16) · Respiratory Tract Infections (16) · Pneumonia (12) · Coronavirus Infections (10) · Pneumonia, Viral (10) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Behavior (1) · Digestive System Diseases (1)
tocilizumab (2) · Azithromycin (1) · COVI-VAC (1) · Glycine (1) · Hydroxychloroquine (1) · Lopinavir (1) · NDV-HXP-S COVID-19 vaccine (1) · Niclosamide (1) · Observation (1) · Ritonavir (1) · Saline Solution (1) · Therapeutics (1) · Vitamin D (1) · baricitinib (1) · fostamatinib (1)
ProgenaBiome (2) · Azienda Ospedaliera Universitaria Integrata Verona (1) · Azienda Ospedaliero, Universitaria Pisana (1) · Beneficência Portuguesa de São Paulo (1) · Bioaraba Health Research Institute (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Centre Hospitalier Universitaire de Nīmes (1) · Grupo Mexicano para el Estudio de la Medicina Intensiva (1) · Hospital Departamental de Villavicencio (1) · I.M. Sechenov First Moscow State Medical University (1) · Institute of Vaccines and Medical Biologicals, Vietnam (1) · Instituto Nacional de Enfermedades Respiratorias (1) · Mahidol University (1) · NMC Specialty Hospital (1) · Rigel Pharmaceuticals (1)
United States (6) · Italy (3) · Mexico (3) · Brazil (2) · France (2) · Spain (2) · Argentina (1) · Belgium (1) · Iran (1) · Iraq (1) · Netherlands (1) · Republic of the Congo (1) · Russia (1) · Thailand (1) · United Arab Emirates (1)
Sabine Hazan, MD (2) · Ahmed S Abdulamir, Professor (1) · Andrey I Yaroshetskiy, Dr.Med.Sc. (1) · Evelina Tacconelli, Professor (1) · Faiq I. Gorial, Prof (1) · Francesco Menichetti, MD (1) · Justin L Grodin, MD, MPH (1) · Mario H Vargas, MSc (1) · Mohammad Javaherian, Ph.D. cand. (1) · Norton Perez, MD (1) · Punnee Pitisutthithum (1) · Sheila Myatra, MD (1)
PMID 22588759, PMID 23666438, PMID 30535520, PMID 31668196, PMID 32031570, PMID 32032529, PMID 32091533, PMID 32146445, PMID 32150360, PMID 32171076, PMID 32187459, PMID 32220207, PMID 32220208, PMID 32227758, PMID 32251638, PMID 32291463, PMID 33307107, PMID 33472855, PMID 34473343, PMID 34580673, PMID 35246024, PMID 35284808, PMID 35577631, PMID 36719885, PMID 37654668, PMID 38773199, PMID 40234280